Celgene

Sutro, Celgene to develop next-gen ADCs and bispecific antibodies

Wednesday, December 19, 2012 09:14 AM

Sutro Biopharma, a San Francisco-based biopharmaceutical company, has formed a collaboration with Celgene, a multinational biopharmaceutical company, to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody.

More... »

Nimbus Discovery names Lynch as executive chairman

Friday, November 2, 2012 03:04 PM

Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.

More... »

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Thursday, October 4, 2012 11:52 AM

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

More... »

VentiRx, Celgene collaborate on novel TLR8 agonist VTX-2337 for cancer

Thursday, October 4, 2012 11:03 AM

VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company focused on novel Toll-like receptor 8 (TLR8) agonists and antagonists, has formed an exclusive, world-wide collaboration with Celgene, an integrated global biopharmaceutical company, for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »

Celgene to acquire Avila Therapeutics

Thursday, January 26, 2012 02:46 PM

Summit, N.J.-based Celgene will acquire privately held Avila Therapeutics of Bedford, Mass., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, for $350 million in cash.

More... »

Rhythm names chief scientific officer

Wednesday, November 30, 2011 12:40 PM

Rhythm has named Lex Van der Ploeg, PhD, chief scientific officer. Van der Ploeg brings to Rhythm more than 25 years of drug development experience in obesity, metabolic diseases, and other therapeutic areas.

More... »

Agios raises $78 million in financing

Thursday, November 17, 2011 11:18 AM

Agios Pharmaceuticals has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the company's rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.

More... »

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

More... »